Logo
x

Search

Subscribe Now

immune thrombocytopenia

Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China

Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China

  • October 28, 2021
Sobi's Dova Pharmaceutical Reports Results of an Online Survey Highlighting Disease Burden and Impact for Patients with Immune Thrombocytopenia

Sobi's Dova Pharmaceutical Reports Results of an Online Survey Highlighting Disease Burden and Impact for Patients with Immune Thr...

  • December 9, 2019
Amgen's Nplate (Romiplostim) Receives FDA's Approval for Immune Thrombocytopenia Aged 1 year and Older

Amgen's Nplate (Romiplostim) Receives FDA's Approval for Immune Thrombocytopenia Aged 1 year and Older

  • December 17, 2018
Amgen Reported Results of ENZ110 (biosimilar, romiplostim) for the Treatment of Chronic Immune Thrombocytopenia

    Amgen Reported Results of ENZ110 (biosimilar, romiplostim) for the Treatment of Chronic Immune Thrombocytopenia

    • July 10, 2023
    HUTCHMED Completes Patient Enrolment of P-III (ESLIM-01) for Primary Immune Thrombocytopenia Patients in China

      HUTCHMED Completes Patient Enrolment of P-III (ESLIM-01) for Primary Immune Thrombocytopenia Patients in China

      • January 3, 2023
      Grifols’ Tavlesse (fostamatinib) Receives NICE Recommendation for the Treatment of Refractory Chronic Immune Thrombocytopenia

        Grifols’ Tavlesse (fostamatinib) Receives NICE Recommendation for the Treatment of Refractory Chronic Immune Thrombocytopenia

        • October 20, 2022
        Zai Lab Partner argenx Report Results of Vyvgart (efgartigimod alfa-fcab) P-III (ADVANCE) Trial for Primary Immune Thrombocytopenia

          Zai Lab Partner argenx Report Results of Vyvgart (efgartigimod alfa-fcab) P-III (ADVANCE) Trial for Primary Immune Thrombocytopeni...

          • May 6, 2022
          Sanofi Publishes Results of Rilzabrutinib in P-I/II Study for the Treatment of Immune Thrombocytopenia in NEJM

            Sanofi Publishes Results of Rilzabrutinib in P-I/II Study for the Treatment of Immune Thrombocytopenia in NEJM

            • April 14, 2022
            Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China

              Hutchmed Initiates P-III ESLIM-01 Trial of HMPL-523 for the Treatment of Immune Thrombocytopenia in China

              • October 28, 2021
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.